03.11.24 -- 21 New Downstream Technologies Being Considered To Fix Capacity Problems

Combining organoids with organ-chips enables the development of more accurate human biological models. Learn how these technologies open the door for new experimental approaches and more.

There are several important factors developers and manufacturers will need to consider to effectively support antibody therapeutics and navigate the trends and challenges on the horizon.

The integration of single-use technologies in upstream and downstream bioprocessing stages has transformed manufacturing by improving efficiency, reducing costs, and minimizing contamination risks.

Compare single-use system bags and learn why both particulate levels and minimizing contamination are important for single-use systems.

Explore how CAI helped the company to navigate complications when implementing SAP and how new solutions are being developed, validated, and implemented to establish this new global ERP system.

Learn what some practical considerations are for implementing NAT-based methods, where concrete recommendations are necessary, and how guidelines can remain relevant for new medicinal products.

The heterogeneity of a biologic product has implications for the final therapy's safety and efficacy. Explore challenges associated with charged variants, including mAbs and fusion proteins.

Learn about three biosafety testing methods that are commonly applied: in vitro adventitious virus (IVV), species-specific virus testing such as minute virus of mice (MVM), and mycoplasma.

Explore how to use and amplify pDNA from the development of recombinant proteins and viral vectors to advanced biotherapeutics such as mRNA vaccines.

Industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.

Discover a single-use automated filtration system designed to deliver robust process control and integrity assurance during the critical purification step. Explore its design features, processing control, and more.

Although veterinary mAbs have achieved commercial success, ongoing discussions and clinical developments surrounding them are expected to outline a clear regulatory pathway in the near future.

Learn about an off-gas analysis system for bioreactors that can provide slightly faster response times than commercially available analyzers.

Modern solutions are continuing to be developed to help those working in biologics overcome historic exosomes / extracellular vesicles challenges.

Technical transfers are one of the most critical, yet challenging steps in drug development; therefore, an effective strategy is essential to accelerate the translation of projects from bench to market.